Treatment with sodium thiosulfate showed no effect on infarct size in STEMI: GIPS IV
Key Points: In the GIPS-IV study, patients with STEMI were randomized to either receiving sodium thiosulfate (STS), an emerging therapy targeting infarct size, or... Read more.
Residual inflammation plays important role in risk of MACE for patients already on lipid-lowering medication: CANTOS Substudy
Key Points: In the original CANTOS, patients with stable CAD post-MI with elevated CRP were randomized to either canakinumab or placebo. In this secondary analysis,... Read more.
Alarmingly Low Rates of Extraction for CIED Infection Despite National and International Recommendations: a Nationwide Observational Study among Over 10,000 Medicare Patients
Key Points Prompt and complete removal of CIED systems is strongly recommended by all major professional societies, however only 1 in 5 patients with CIED infection... Read more.
Less Structural Valve Deterioration at 5 years with TAVR: Insights from CoreValve/SURTAVI Trials
Key Points: As transcatheter aortic valve replacement (TAVR) has experienced expanded indications into patients with low and intermediate surgical risk, conversations... Read more.
CLASP-TR demonstrates significant improvement in tricuspid regurgitation up to one year after procedure.
Key Points Tricuspid regurgitation is a debilitating valve disorder characterized by shortness of breath, fatigue, and recurrent hospitalization for fluid retention.... Read more.
The PARTITA Trial: VT Ablation After the First Episode of VT Treated with Shock is Superior to Conservative Treatment Among Patients with Ischemic and Non-Ischemic Cardiomyopathy.
Key Points While VT ablation has been associated with improved survival, the most ideal time to undergo VT ablation remains undefined. PARTITA was the first clinical... Read more.
Patirometer allows for maintenance of target doses of GDMT in patients with hyerkalemia: DIAMOND trial
Key Points Optimal medical therapy for patients with Heart Failure with Reduced Ejection Fraction (HFrEF) compromises of renin-angiotensin-aldosterone-system inhibitors... Read more.
Uncoupling Hemostasis from Thrombosis: A Promising Comparison of Oral FXIa Inhibitor Asundexian Versus Apixaban in Patients with Atrial Fibrillation – But More Data Are Needed.
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral anticoagulation by finally uncoupling hemostasis from thrombosis and potentially allowing... Read more.
Alirocumab initiation after MI associated with lower plasma atheroma volume: PACMAN-AMI
Key Points PCSK-9 inhibitors have emerged as a viable treatment option patients hypercholesterolemia despite adequate tolerance of statin therapies. The role of... Read more.
Mavacamten improves LVOT gradients in patients with HCM: EXPLORER-LTE
Key Points: In the EXPLORER-LTE study, patients with severely symptomatic obstructive HCM previously enrolled in the EXPLORER-HCM study underwent ongoing therapy... Read more.